Partnerships

Triphase Accelerator Corporation expands collaboration with Celgene in developing Marizomib to treat gliomas

Company initiating two new clinical trials for recurrent and newly diagnosed malignant gliomas TORONTO and SAN DIEGO, (May 03, 2016) – Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it is expanding its current collaboration with Celgene Corp. in the development of marizomib for the potential treatment of malignant gliomas. The two companies will collaborate on a Phase 2 study using marizomib (MRZ) as monotherapy in recurrent glioblastoma, as well as a Phase ... Read more

QD Solar receives $2.55 million from Sustainable Development Technology Canada (SDTC)

TORONTO (March 17, 2016) — QD Solar, a Canadian technology company created by the University of Toronto (U of T) and MaRS Innovation, has received $2.55 million from the Sustainable Development Technology Canada (SDTC). QD Solar’s funding — announced March 4, 2016 in Edmonton, Alberta by the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development — will galvanize a larger $8.7 million project to revolutionize conventional solar panels that waste a large portion of the available energy in sunlight because ... Read more

XENiOS® invests $2.6 million in XOR-Labs Toronto

Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017 HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto (“XOR”), a spin-off of Toronto General Hospital at University Health Network (UHN), the world’s leading center for lung transplantation, created in partnership with MaRS Innovation. This announcement was covered in FierceMedicalDevices and Cystic Fibrosis News Today. VICE featured XOR's life-saving lung transplant technology ... Read more

Accel-Rx and BDC Capital make second portfolio investment in ScarX Therapeutics

MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis). Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ... Read more

Ontario advancing nine medical research projects in cancer, heart disease and sleep apnea to market

Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children. Applications for the next MSc PoP granting round are open until March 4, 2016. To ... Read more

UTEST grad eQOL receives $350,000 for remote patient monitoring program

UTEST graduate eQOL has received $350,000 from the Ontario Government to support patients managing their kidney dialysis at home. eQOL's solutions use mobile tablets technology to support patients in managing independent care at home. The funding, part of an Ontario Centres of Excellence program to support technology used to remotely monitor and care for Ontario patients, was announced December 1, 2015 and covered in Canadian Healthcare Technology. eQOL has partnered with London Health Sciences Centre, Ontario Telemedicine Network and the Kidney Foundation of Canada ... Read more

Triphase to present Marizomib clinical and preclinical data at American Society of Hematology’s annual meeting

TORONTO and SAN DIEGO (December 8, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in patients with relapsed and refractory multiple myeloma will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH). The company will also present preclinical data on marizomib demonstrating synergistic activity in combination with pomalidomide. Marizomib is a novel ... Read more

MaRS Innovation partners with Chris Hadfield’s Generator event

Win a pair of Generator tickets or a signed copy of a Hadfield book! Today, MaRS Innovation’s launching our new Wordpress website, built with feedback and input from our community (thanks to all who took the web survey back in June and please be patient with us as we make tweaks and adjustments this week). We're excited because our website is where we talk about our role in advancing Toronto’s innovation ecosystem. We share news from our portfolio of companies and technologies, which ... Read more

Encycle Therapeutics raises $2.85 million to advance macrocycle platform and pipeline

TORONTO, ON (September 30, 2015) — Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund. This news was covered in PEHub, BetaKit and TechVibes. The funding will support ongoing development of Encycle’s unique nacellin platform chemistry and advance the company’s ... Read more

MaRS Innovation sponsoring Angels’ Den competition

Prima IP co-sponsoring the Ryerson University and St. Michael’s Hospital event When your business demands staying current with the newest inventions springing up across 15 academic members, keeping pace with what’s happening is half the challenge. That’s part of the reason why MaRS Innovation and Prima IP are sponsoring winners of an Angels’ Den competition involving the Institute for Biomedical Engineering, Science and Technology (iBEST). iBEST is a partnership between Ryerson University and St. Michael's Hospital that brings together Ryerson's engineering and science strengths ... Read more
Page 3 of 1512345...10...Last »